TL;DR

Cannabis use among adults aged 65 and older is increasing, and many older adults are exploring medical cannabis products to manage chronic pain, poor sleep, anxiety, and other age-related symptoms. Emerging research suggests that some patients may experience meaningful improvements in pain interference, sleep quality, anxiety, and quality of life. However, much of the favorable evidence comes from observational studies, which can identify associations but cannot prove that cannabis caused those outcomes.

The strongest safety evidence shows that THC-containing cannabis products can increase dizziness, drowsiness, impaired coordination, mobility and balance problems, and cognitive or perceptual effects. These risks can be especially significant for older adults with frailty, osteoporosis, fall risk, dementia, cardiovascular disease, or complex medication regimens. Edibles deserve particular caution because delayed onset can lead to repeated dosing and prolonged impairment.

Cannabis is not one standardized treatment. Potential benefits and risks depend on the patient, the condition being treated, the product’s THC and CBD content, dose, route of administration, timing, prior cannabis exposure, and the person’s other medications and medical conditions.

The most useful clinical question is not, “Does cannabis work for seniors?” It is:

For this patient, for this condition, using this product at this dose and by this route, in the context of these other medications, do the potential benefits outweigh the potential risks?

Older adults should discuss cannabis use with an appropriate clinician and should not independently change prescribed medications, including opioids, sedatives, antidepressants, or sleep medications, based on cannabis use alone.

Cannabis use among adults 65 and older is increasing. Recent studies suggest potential benefits involving pain, sleep, anxiety, and quality of life, while stronger safety evidence identifies meaningful risks associated particularly with THC. The science is not settled. It is increasingly clear, however, that cannabis use in older patients deserves the same individualized clinical analysis we apply to other therapies.

For more than 20 years, I worked in long-term care and senior housing, including skilled nursing facilities and assisted living. For the past decade, I have led DocMJ, where physicians evaluate patients for medical cannabis. Those experiences have given me an unusual vantage point on one of the more interesting developments at the intersection of cannabis and health care: the growing use of cannabis by older adults.

For years, much of the public conversation around cannabis focused on legalization. The more interesting questions today are increasingly clinical. Why are older adults using cannabis? What conditions are they trying to address? Are they experiencing measurable benefits? What do we know about THC and CBD in an aging population? And, perhaps most importantly, what does the evidence show, and what does it not yet show?

Cannabis Use Among Adults 65 and Older Is Increasing

A 2025 study published in JAMA Internal Medicine examined current cannabis use among U.S. adults age 65 and older. Researchers found that past-month cannabis use increased from 4.8% in 2021 to 7.0% in 2023, an increase of about 46% in only two years. The increase was also observed among older adults with several chronic conditions, including heart conditions, diabetes, hypertension, cancer, COPD, and two or more chronic medical conditions.

The study has important limitations. It did not sample institutionalized adults, distinguish medical from recreational use, or identify the cannabinoid products people were using. Still, the prevalence trend matters because older adults often have the complex medical histories, medication burdens, and functional vulnerabilities that make both potential benefit and potential harm more consequential.

Why Older Adults Are Considering Cannabis

A May 2026 JAMA Network Open study examined 169 adults age 60 and older who were considering edible cannabis for pain, sleep, or mental-health concerns. Participants described motivations that included seeking alternatives to pharmaceutical medications, frustration with prior treatments, and managing new or worsening symptoms associated with aging.

Among participants who purchased products, 57.5% selected a THC-and-CBD combination, 28.7% selected CBD-only products, and 13.8% selected THC-only products. The study also documented uncertainty around dosing, psychoactive effects, and product selection.

This was not an efficacy trial, and it cannot establish how older adults generally use cannabis. What it does show is that at least some older adults are approaching cannabis intentionally as a tool for symptom management. That makes informed clinical guidance more important, not less.

What the Outcomes Research Suggests

One of the most significant recent studies is the Medical Cannabis in Older Patients Study, or MCOPS, published in 2025. Researchers prospectively followed 299 medical-cannabis patients over age 50 for six months. The average participant was 66.7 years old, and approximately 90% used medical cannabis for pain-related conditions such as chronic pain and arthritis.

At six months, 45% of participants with available pain data achieved a clinically meaningful improvement in pain interference, and 45% of participants with available sleep data achieved a clinically meaningful improvement in sleep quality. Quality-of-life measures also improved. Nearly half of participants taking co-medications at baseline had reduced their use by the end of the study period, and no serious adverse events were reported.

Those are encouraging findings, but they are not proof of causation. MCOPS was a prospective observational study, not a randomized placebo-controlled trial. Participants chose to initiate medical cannabis, and the study also had substantial attrition and non-use over time. Patient expectations, selection effects, concurrent clinical changes, and other unmeasured factors could have influenced the outcomes. The appropriate conclusion is that medical-cannabis treatment was associated with meaningful improvements in a substantial subset of participants, not that cannabis was proven to cause those improvements.

Other Studies Show Similar Signals

Other prospective studies point in the same general direction. A 2025 study in Psychiatry followed 106 medical-cannabis users ages 55 to 74 through repeated assessments in daily life. Cannabis use, measured through subjective intoxication, was associated with lower subsequent pain, anxiety, and depression, as well as lower anxiety and better sleep later that night. The authors appropriately described these as momentary improvements, not evidence of long-term therapeutic efficacy.

A University of Florida prospective study of 46 adults initiating medical cannabis for chronic pain found reductions in momentary pain and anxiety and improvements in sleep. At three months, participants also reported improvements in pain interference, depression, sleep, and quality of life compared with baseline. The sample was small, with a mean age of 55.7, so the findings should not be generalized to all older adults.

An earlier prospective study focused specifically on patients over age 65, with a mean age of 74.5. Among six-month respondents, median reported pain declined from 8 to 4 on a 10-point scale, and 18.1% reported stopping opioid analgesics or reducing their dose. Dizziness and dry mouth were among the most commonly reported adverse effects. Again, this was observational research, not randomized proof.

Why the Evidence Is Still Difficult to Interpret

The most important limitation of the favorable evidence is methodological. Observational studies are valuable for understanding how patients use cannabis in the real world, what benefits they report, and which adverse effects occur. They generally cannot establish causation as reliably as well-designed randomized, placebo-controlled trials.

There is another problem: “cannabis” is not one standardized intervention. Clinical effects can vary with THC concentration, CBD concentration, THC-to-CBD ratio, dose, route of administration, formulation, timing, frequency of use, prior exposure, and the individual patient’s metabolism and medical history. An oral edible, a tincture, a vaporized product, and a high-THC flower product can have very different onset times, peak effects, durations, and safety profiles.

Nor are “older adults” a uniform population. A healthy 66-year-old taking few medications presents a different clinical question from an 84-year-old with dementia, atrial fibrillation, anticoagulation, osteoporosis, gait instability, chronic kidney disease, and several sedating medications. Age matters, but frailty, cognition, mobility, cardiovascular risk, psychiatric history, medication burden, and treatment goals may matter more.

A 2025 systematic review in the Journal of the American Geriatrics Society underscores the point. The older-adult evidence base remains limited and heterogeneous, with substantial variation in products, doses, populations, routes, and outcomes. That makes broad claims about efficacy inappropriate.

The Risks Deserve Equal Attention

One of the strongest recent safety analyses was published in Age and Aging in 2024. Researchers conducted a systematic review and meta-analysis of 58 randomized clinical trials involving 6,611 middle-aged and older adults, with mean participant ages across the studies ranging from 50 to 87.

THC-containing cannabinoid medicines were associated with increased adverse effects, several of which increased with dose. These included dizziness and lightheadedness, drowsiness, mobility and balance difficulties, coordination problems, and thinking or perceptual effects. The analysis did not find a statistically significant increase in serious adverse events, withdrawals, or deaths with THC-containing cannabinoid medicines, but the so-called non-serious effects are not trivial in an aging population.

A brief episode of dizziness or impaired balance can trigger a very different chain of events in an older adult with osteoporosis or gait instability: fall, fracture, surgery, hospitalization, rehabilitation, loss of mobility, and potentially loss of independence. That is why the useful question is not simply whether cannabis is “safe.” It is safe for whom, at what dose, with what product, for what purpose, and in combination with what other medications?

Edibles, Impairment, and Functional Risk

Edibles deserve particular attention because oral cannabis has a delayed onset. Someone who does not feel an effect quickly may take more before the first dose has reached its full effect, increasing the risk of excessive intoxication or prolonged impairment.

A 2024 JAMA Internal Medicine study examined cannabis-poisoning emergency-department visits among Ontario adults age 65 and older. Rates increased from 5.8 visits per 100,000 person-years before legalization to 15.4 after dried cannabis was legalized and 21.1 after edible cannabis became legally available. The study could not establish that edibles alone caused the increase, and the authors identified broader commercialization and other temporal factors as possible contributors. The findings nevertheless reinforce the need for careful education about dose, delayed onset, and repeat dosing.

Impairment is also relevant even in regular users. A 2024 JAMA Network Open study of 31 regular cannabis users ages 65 to 79 found increased lane weaving and decreased driving speed 30 minutes after participants smoked their preferred legal cannabis product. Participants continued to report diminished driving ability three hours later. The sample was small, but the practical point is important: regular use does not necessarily eliminate impairment.

Polypharmacy May Be One of the Most Important Questions

Cannabis is also a polypharmacy issue. Older adults frequently take medications that affect blood pressure, alertness, bleeding risk, coordination, mood, sleep, or cognition. THC or CBD may add to those effects, interact with medications, or make new symptoms harder to interpret.

An older adult who develops dizziness, confusion, sedation, or unsteadiness may be experiencing a cannabis-related effect, an excessive THC dose, an interaction with another medication, dehydration, hypotension, infection, hypoglycemia, arrhythmia, stroke, or another medical problem. Cannabis should not become the default explanation for new symptoms. It should be part of the clinical assessment.

The observational finding that some patients reduce other medications after initiating medical cannabis is worth studying. It is not a license for self-directed deprescribing. Changes to opioids, sedatives, antidepressants, or other prescribed medications should remain clinical decisions made with appropriate oversight.

A Better Clinical Framework

The evidence supports caution without stigma. Instead of asking whether cannabis is broadly “good” or “bad” for seniors, clinicians and patients should evaluate six variables: the patient, the condition, the product, the dose, the route, and the medication context.

The patient matters because frailty, cognition, fall history, cardiovascular status, psychiatric history, kidney and liver function, and prior cannabis exposure can change the risk profile. The condition matters because an intervention should have a defined treatment goal. The product matters because THC and CBD are not interchangeable. Dose and route matter because they influence onset, peak effect, duration, and impairment. Medication context matters because older adults often have complex regimens in which additive sedation, blood-pressure effects, or drug interactions may be clinically significant.

That framework leads to a more useful question than “Does cannabis work?”: For this patient, for this condition, using this product at this dose and by this route, in the context of these other medications, do the potential benefits outweigh the potential risks?

Better Research Is Underway

Researchers are now trying to answer these questions more rigorously. In 2026, investigators published the protocol for the Study on Medical Marijuana and Its Long-Term Effects on Older Adults, or SMILE. The prospective cohort study is designed to follow 440 adults age 50 and older with chronic pain for 12 months, including approximately 330 participants initiating medical marijuana and a 110-person comparison group.

The study is designed to examine pain alongside physical, emotional, and cognitive functioning, quality of life, product characteristics, and adverse effects. Those are exactly the questions the field needs answered: which patients benefit, which do not, how dose and THC-to-CBD ratio influence outcomes, what happens to cognition over time, and which patients are most susceptible to adverse effects.

A Brief Implication for Senior Care

There is a downstream implication for organizations that care for older adults. As more people use cannabis while living independently, some will enter assisted living, home health, hospice, and other care settings already using it. That creates legitimate questions around medication reconciliation, self-administration, storage, impairment, staff responsibilities, and resident safety.

Those questions are necessarily jurisdiction-specific. State cannabis law, healthcare licensure requirements, federal considerations, the resident’s capacity, and the particular product or route can all matter. A thoughtful cannabis policy is therefore a governance policy, not necessarily an endorsement or accommodation policy.

The larger point is clinical: healthcare organizations serving older adults can no longer treat cannabis use as an unusual exception. Increasingly, it is another part of the patient’s health history that needs to be understood and managed appropriately.

Where the Science Leaves Us

The current evidence does not support saying that medical cannabis has been proven broadly effective for older adults. It would also be unreasonable to dismiss the accumulating evidence of potential benefit. Multiple prospective studies report improvements involving pain, sleep, anxiety, and quality of life. Randomized evidence identifies real, sometimes dose-dependent risks associated particularly with THC. Larger and better-designed studies are underway.

That is not scientific certainty. It is an evolving evidence base. The responsible response is neither uncritical advocacy nor reflexive dismissal. It is to follow the evidence, acknowledge its limitations, understand the risks, and continue asking better questions.

For an individual patient, the most useful question is not simply, “Does cannabis work?” It is whether, for this patient, this condition, this product, this dose, this route, and this medication profile, the potential benefits outweigh the potential risks.

That is ultimately a medical question. And that is where the conversation about cannabis and older adults increasingly belongs.

Important disclaimer: This article is for educational purposes only and is not medical or legal advice. Older adults should consult an appropriate clinician before beginning, stopping, or changing cannabis use or any prescribed medication. Cannabis laws and healthcare regulations vary by jurisdiction.

Research Cited

Aaron Bloom

Aaron Bloom, an experienced healthcare attorney, serves as the CEO of DocMJ and Medwell Health and Wellness Centers, where he has overseen the organizations’ mission and growth since 2016. In addition to his leadership roles, Aaron serves on the Board of Directors for Waterfall Bank, bringing his expertise in healthcare, compliance, and strategic growth to the financial services sector.

Aaron’s passion for improving patients’ lives stems from more than 20 years of owning, operating, and representing traditional healthcare organizations. Throughout his career, he has remained committed to finding better ways to relieve suffering and expand access to innovative, patient-centered care. As CEO, Aaron works each day to help patients achieve better health and wellness through the therapeutic benefits of medical cannabis and other evidence-based alternative medicines.

Cannabis and Older Adults: What the Research Shows About Benefits, Risks, and Clinical Guidance